Luccarelli James, Clauss Jacqueline A, York Tasia, Baldwin Isaac, Vandekar Simon, McGonigle Trey, Fricchione Gregory, Fuchs Catherine, Smith Joshua R
Harvard Medical School, Boston, MA, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Gen Hosp Psychiatry. 2025 Jul-Aug;95:133-139. doi: 10.1016/j.genhosppsych.2025.05.003. Epub 2025 May 7.
Catatonia is a neuropsychiatric disorder that occurs in pediatric patients with a range of associated medical, psychiatric, and neurodevelopmental disorders (NDDs). This study describes hospital care of pediatric catatonia patients and compares treatments for neurotypical patients and those with NDDs.
Retrospective cohort study from 1/1/2018 to 6/1/2023 of two academic medical centers of patients aged 18 and younger with catatonia. Patients were retrospectively assessed using the clinical global impressions-improvement (CGI-I) by two independent reviewers.
One hundred sixty-five patients were hospitalized for catatonia, of whom 50.3 % had an NDD. Median age was 15. One hundred sixty-four patients were treated with a benzodiazepine, with a median maximum 24-hour dose of 6 mg lorazepam-equivalents, which did not differ for patients with and without NDDs. Electroconvulsive therapy (ECT) was utilized in 14.5 % of patients. Median length of medical hospitalization was 5 days and hospitalizations were longer in neurotypical patients than in patients with NDDs. In an ordinal regression model, the probability of observing at least "much improvement" (CGI < 3) was 88.3 % (95 % CI: 82.4 % to 92.3 %), with patients with a non-medical primary diagnosis and an NDD having a lower odds of response than non-medical primary diagnosis without an NDD.
The probability of patients achieving a CGI-I score indicating at least "much improvement" was 88.3 %. Administered benzodiazepine dose and ECT treatment were similar for all patients, but neurotypical patients had longer hospitalizations than those with NDDs and had a higher odds of a more favorable clinical response for patients with non-medical primary diagnoses. Research under controlled conditions is needed to optimize and endure equitable catatonia treatment in youth.
紧张症是一种神经精神障碍,发生于患有一系列相关医学、精神和神经发育障碍(NDDs)的儿科患者中。本研究描述了儿科紧张症患者的住院治疗情况,并比较了对神经发育正常患者和患有NDDs患者的治疗方法。
对2018年1月1日至2023年6月1日期间两个学术医疗中心18岁及以下患有紧张症的患者进行回顾性队列研究。由两名独立评审员使用临床总体印象改善量表(CGI-I)对患者进行回顾性评估。
165例患者因紧张症住院,其中50.3%患有NDDs。中位年龄为15岁。164例患者接受了苯二氮䓬类药物治疗,24小时最大剂量中位数为6毫克劳拉西泮等效剂量,患有和未患有NDDs的患者之间无差异。14.5%的患者接受了电休克治疗(ECT)。医疗住院时间中位数为5天,神经发育正常患者的住院时间比患有NDDs的患者更长。在有序回归模型中,观察到至少“明显改善”(CGI<3)的概率为88.3%(95%CI:82.4%至92.3%),非医学原发性诊断且患有NDDs的患者反应几率低于非医学原发性诊断且未患有NDDs的患者。
患者获得表明至少“明显改善”的CGI-I评分的概率为88.3%。所有患者使用的苯二氮䓬类药物剂量和ECT治疗相似,但神经发育正常患者的住院时间比患有NDDs的患者更长,对于非医学原发性诊断的患者,其临床反应更有利的几率更高。需要在可控条件下进行研究,以优化并确保青少年紧张症治疗的公平性。